Related Experiment Videos
Integrated acidity and rabeprazole pharmacology.
J D Gardner1, C Perdomo, S Sloan
1Science for Organizations Inc., Chatham, NJ 07928, USA. gardnerj@bellatlantic.net
Alimentary Pharmacology & Therapeutics
|March 6, 2002
Summary
Rabeprazole effectively reduces gastric and oesophageal acidity in GERD patients. Integrated acidity measurements offer a sensitive method to assess treatment effects and understand GERD pathophysiology.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Integrated gastric and oesophageal acidity quantify acidity over time.
- Rabeprazole is a proton pump inhibitor for gastro-oesophageal reflux disease (GERD).
Purpose of the Study:
- To determine rabeprazole's onset, duration, and effect on acidity in GERD patients.
- Utilize integrated acidity measurements for novel insights.
Main Methods:
- Recruited GERD patients with specific pH criteria.
- Measured 24-h gastric and oesophageal pH on days 1 and 7 of rabeprazole (20 mg) dosing.
- Calculated integrated acidity from time-weighted average hydrogen ion concentrations.
Main Results:
- Rabeprazole (20 mg) achieved 89% gastric and 95% oesophageal acidity inhibition at steady-state.
- First dose showed at least 70% of steady-state inhibition.
- Onset of action varied (4-7 hours) based on GERD subtype (monophasic/biphasic).
- Integrated acidity was more sensitive than time pH ≤ 4.
Conclusions:
- Integrated acidity measurements provide quantitative data on GERD pathophysiology.
- These measurements offer novel insights into the impact of antisecretory agents like rabeprazole.